Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

OGN PEER ANALYSIS

Organon & Co — metric-by-metric comparison with peers and the industry median

OGNOrganon & Co

🇺🇸 USA · NYSE · Healthcare · Drug Manufacturers - General

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Drug Manufacturers - General

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial HealthDividend
OGNIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
OGN+37.3%AZN+38.8%GRF-13.3%GSK+46.5%AZN+36.0%BAYN+95.9%
Year-to-Date (YTD)
OGN+89.9%AZN+3.3%GRF-15.3%GSK+10.6%AZN+7.5%BAYN+38.7%
1-Year
Split-adjusted
OGN+37.3%BIIB+56.9%
Year-to-Date (YTD)
OGN+89.9%BIIB+18.4%

Key Metric Comparison

P/E

Lower is better
OGN14.49AZN28.08GRF14.86GSK13.86AZN28.27BAYN—Median 22.54

ROE

Higher is better
OGN34.0%AZN23.7%GRF7.5%GSK36.4%AZN23.5%BAYN-7.0%Median 23.7%

Net Margin

Higher is better
OGN4.0%AZN17.2%GRF5.6%GSK17.8%AZN17.2%BAYN-4.8%Median 15.0%

Revenue Growth

Higher is better
OGN-2.1%AZN9.7%GRF0.9%GSK4.0%AZN9.9%BAYN-2.9%Median 3.3%

P/E

Lower is better
OGN14.49BIIB22.54Median 22.54

ROE

Higher is better
OGN34.0%BIIB7.7%Median 23.7%

Net Margin

Higher is better
OGN4.0%BIIB13.9%Median 15.0%

Revenue Growth

Higher is better
OGN-2.1%BIIB0.4%Median 3.3%

All Metrics

Valuation
MetricOGNAZNGRFGSKAZNBAYNInd. Median
P/E14.4928.0814.8613.86●28.27—22.54
P/B3.956.201.13●4.536.201.744.53
EV/EBITDA7.97●15.5710.538.3415.6923.5313.48
P/S0.58●4.830.832.464.861.113.14
Financial Health
MetricOGNAZNGRFGSKAZNBAYNInd. Median
Current Ratio1.970.912.47●0.790.911.061.25
Debt/Equity948.9%71.7%●177.2%106.7%71.7%●134.8%94.3%
NetDebt/EBITDA5.391.28●6.221.351.299.191.35
Profitability
MetricOGNAZNGRFGSKAZNBAYNInd. Median
Net Margin4.0%17.2%5.6%17.8%●17.2%-4.8%15.0%
ROE34.0%23.7%7.5%36.4%●23.5%-7.0%23.7%
ROA1.9%9.5%●2.0%9.4%9.4%-2.0%8.0%
EBITDA Margin22.4%33.8%19.3%35.3%●33.7%7.7%28.4%
Growth + Dividend
MetricOGNAZNGRFGSKAZNBAYNInd. Median
Rev. Growth-2.1%9.7%0.9%4.0%9.9%●-2.9%3.3%
NI Growth-67.2%32.9%112.7%●84.9%33.7%—32.9%
Div. Yield0.6%2.2%2.1%3.3%●0.2%0.2%2.1%
Payout8.9%47.0%30.8%44.5%47.3%-5.9%45.7%
Valuation
MetricOGNBIIBInd. Median
P/E14.49●22.5422.54
P/B3.951.66●4.53
EV/EBITDA7.97●12.2913.48
P/S0.58●3.143.14
Financial Health
MetricOGNBIIBInd. Median
Current Ratio1.973.06●1.25
Debt/Equity948.9%35.2%●94.3%
NetDebt/EBITDA5.390.84●1.35
Profitability
MetricOGNBIIBInd. Median
Net Margin4.0%13.9%●15.0%
ROE34.0%●7.7%23.7%
ROA1.9%4.8%●8.0%
EBITDA Margin22.4%27.4%●28.4%
Growth + Dividend
MetricOGNBIIBInd. Median
Rev. Growth-2.1%0.4%●3.3%
NI Growth-67.2%-7.2%●32.9%
Div. Yield0.6%—2.1%
Payout8.9%—45.7%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on OGN

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.